BriaCell $BCTX impresses for #ASCO25 Phase 2 data shows survival and clinical benefit that meets or beats FDA-approved therapies in heavily pretreated MBC patients and no treatment-related discontinuations.
https://globenewswire.com/news-release/2025/0...-2025.html #STOCKS #STOCKSTOBUY #INVESTORS #STOCKS #TRADER #BCTX @smallcapvoice